Thalidomide treatment in multiple myelom
β
Kathrin Strasser; Heinz Ludwig
π
Article
π
2002
π
Elsevier Science
π
English
β 139 KB
Thalidomide was first evaluated in patients with refractory multiple myeloma in the mid-90s. Based on the promising results achieved in these patients, the drug was subsequently used in earlier stages of the disease. Meanwhile, numerous phase II studies have been published using different doses and